CG001419
Pain
Phase 1Active
Key Facts
About Cullgen
Cullgen is a clinical-stage biotechnology company pioneering a next-generation targeted protein degradation platform called uSMITE™ to drug traditionally 'undruggable' targets. The company has advanced programs into Phase 1 clinical trials, including a non-opioid candidate for pain, and is developing Degrader-Antibody Conjugates (DACs) as a novel therapeutic modality. In March 2026, Gyre Therapeutics entered into an agreement to acquire Cullgen, highlighting the strategic value of its platform and pipeline. Cullgen's approach aims to expand the drug design paradigm for oncology, pain, and inflammation.
View full company profileTherapeutic Areas
Other Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxycodone Patch | Avecho Biotechnology | Preclinical |
| Oxymorphone Patch | Avecho Biotechnology | Preclinical |
| Desmetramadol | Syntrix Pharmaceuticals | Clinical Development |
| Diclofenac Potassium Powder for Oral Solution | Patrin Pharma | Approved |
| Proprietary Pain Program(s) | Oblique Therapeutics | Pre-clinical |
| Pain Management APIs | Noramco | Commercial |
| Dipendium (Diclofenac Potassium) | NovaMedica | Approved |
| Na ion channel TicTACs | Solu Therapeutics | Preclinical |
| Infusional Pain Management (e.g., Paracetamol) | Galenica Senese | Commercial |
| NCEs for Pain Management | Ipca Laboratories | Preclinical/Discovery |
| XEN1701 | Xenon Pharmaceuticals | Phase 1 |